Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 735

1.

Forty-five years in oncology, 25 years with Acta Oncologica.

Glimelius B.

Acta Oncol. 2018 Nov 29:1-6. doi: 10.1080/0284186X.2018.1547841. [Epub ahead of print] No abstract available.

PMID:
30489167
2.

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.

Robles-Zurita J, Boyd KA, Briggs AH, Iveson T, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Segelov E, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Hughes R, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.

Br J Cancer. 2018 Nov;119(11):1332-1338. doi: 10.1038/s41416-018-0319-z. Epub 2018 Nov 13.

PMID:
30420616
3.

Do we make progress in elderly patients with metastatic colorectal cancer?

Glimelius B, Pfeiffer P.

Acta Oncol. 2018 Nov;57(11):1422-1426. doi: 10.1080/0284186X.2018.1535189. Epub 2018 Nov 1. No abstract available.

PMID:
30384805
4.

An audit of performance, interpretation, and influence of pretherapeutic MRI in rectal cancer: a Swedish population-based cohort study.

Elliot AH, Blomqvist L, Sigurdsson A, Martling A, Johansson H, Glimelius B, Nilsson PJ.

Acta Radiol. 2018 Oct 15:284185118806638. doi: 10.1177/0284185118806638. [Epub ahead of print]

PMID:
30322292
5.

Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia.

McMaster ML, Berndt SI, Zhang J, Slager SL, Li SA, Vajdic CM, Smedby KE, Yan H, Birmann BM, Brown EE, Smith A, Kleinstern G, Fansler MM, Mayr C, Zhu B, Chung CC, Park JH, Burdette L, Hicks BD, Hutchinson A, Teras LR, Adami HO, Bracci PM, McKay J, Monnereau A, Link BK, Vermeulen RCH, Ansell SM, Maria A, Diver WR, Melbye M, Ojesina AI, Kraft P, Boffetta P, Clavel J, Giovannucci E, Besson CM, Canzian F, Travis RC, Vineis P, Weiderpass E, Montalvan R, Wang Z, Yeager M, Becker N, Benavente Y, Brennan P, Foretova L, Maynadie M, Nieters A, de Sanjose S, Staines A, Conde L, Riby J, Glimelius B, Hjalgrim H, Pradhan N, Feldman AL, Novak AJ, Lawrence C, Bassig BA, Lan Q, Zheng T, North KE, Tinker LF, Cozen W, Severson RK, Hofmann JN, Zhang Y, Jackson RD, Morton LM, Purdue MP, Chatterjee N, Offit K, Cerhan JR, Chanock SJ, Rothman N, Vijai J, Goldin LR, Skibola CF, Caporaso NE.

Nat Commun. 2018 Oct 10;9(1):4182. doi: 10.1038/s41467-018-06541-2.

6.

Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers.

Hammarström K, Mezheyeuski A, Korsavidou Hult N, Sjöblom T, Glimelius B.

Eur J Surg Oncol. 2018 Dec;44(12):1858-1864. doi: 10.1016/j.ejso.2018.07.063. Epub 2018 Aug 18.

PMID:
30201417
7.

Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish Population.

Osterman E, Glimelius B.

Dis Colon Rectum. 2018 Sep;61(9):1016-1025. doi: 10.1097/DCR.0000000000001158.

PMID:
30086050
8.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
9.

Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?

Bhoday J, Glimelius B, Tait D, Glynne-Jones R, Adams R, Brown G.

Colorectal Dis. 2018 May;20 Suppl 1:97-99. doi: 10.1111/codi.14088.

PMID:
29878687
10.

Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome.

Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK.

Br J Cancer. 2018 Jun;118(12):1609-1616. doi: 10.1038/s41416-018-0115-9. Epub 2018 Jun 6.

PMID:
29872151
11.

Preoperative radiotherapy or chemoradiotherapy in rectal cancer - Is survival improved? An update of the "Nordic" LARC study in non-resectable cancers.

Brændengen M, Glimelius B.

Radiother Oncol. 2018 Jun;127(3):392-395. doi: 10.1016/j.radonc.2018.05.004. Epub 2018 May 16.

PMID:
29778486
12.

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.

Wang SS, Carrington M, Berndt SI, Slager SL, Bracci PM, Voutsinas J, Cerhan JR, Smedby KE, Hjalgrim H, Vijai J, Morton LM, Vermeulen R, Paltiel O, Vajdic CM, Linet MS, Nieters A, de Sanjose S, Cozen W, Brown EE, Turner J, Spinelli JJ, Zheng T, Birmann BM, Flowers CR, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Albanes D, Weinstein SJ, Teras LR, Diver WR, Lax SJ, Travis RC, Kaaks R, Riboli E, Benavente Y, Brennan P, McKay J, Delfau-Larue MH, Link BK, Magnani C, Ennas MG, Latte G, Feldman AL, Doo NW, Giles GG, Southey MC, Milne RL, Offit K, Musinsky J, Arslan AA, Purdue MP, Adami HO, Melbye M, Glimelius B, Conde L, Camp NJ, Glenn M, Curtin K, Clavel J, Monnereau A, Cox DG, Ghesquières H, Salles G, Bofetta P, Foretova L, Staines A, Davis S, Severson RK, Lan Q, Brooks-Wilson A, Smith MT, Roman E, Kricker A, Zhang Y, Kraft P, Chanock SJ, Rothman N, Hartge P, Skibola CF.

Cancer Res. 2018 Jul 15;78(14):4086-4096. doi: 10.1158/0008-5472.CAN-17-2900. Epub 2018 May 7.

13.

Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.

Goey KKH, Mahmoud R, Sørbye H, Glimelius B, Köhne CH, Sargent DJ, Punt CJA, van Oijen MGH, Koopman M.

Eur J Cancer. 2018 Jun;96:115-124. doi: 10.1016/j.ejca.2018.03.026. Epub 2018 May 2. Review.

PMID:
29729562
14.

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Kleinstern G, Camp NJ, Goldin LR, Vachon CM, Vajdic CM, de Sanjose S, Weinberg JB, Benavente Y, Casabonne D, Liebow M, Nieters A, Hjalgrim H, Melbye M, Glimelius B, Adami HO, Boffetta P, Brennan P, Maynadie M, McKay J, Cocco PL, Shanafelt TD, Call TG, Norman AD, Hanson C, Robinson D, Chaffee KG, Brooks-Wilson AR, Monnereau A, Clavel J, Glenn M, Curtin K, Conde L, Bracci PM, Morton LM, Cozen W, Severson RK, Chanock SJ, Spinelli JJ, Johnston JB, Rothman N, Skibola CF, Leis JF, Kay NE, Smedby KE, Berndt SI, Cerhan JR, Caporaso N, Slager SL.

Blood. 2018 Jun 7;131(23):2541-2551. doi: 10.1182/blood-2017-11-814608. Epub 2018 Apr 19.

PMID:
29674426
15.

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.

Lancet Oncol. 2018 Apr;19(4):562-578. doi: 10.1016/S1470-2045(18)30093-7.

16.

Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases.

Cashin PH, Mahteme H, Syk I, Frödin JE, Glimelius B, Graf W.

Eur J Surg Oncol. 2018 Jul;44(7):983-990. doi: 10.1016/j.ejso.2018.02.012. Epub 2018 Feb 21.

PMID:
29530346
17.

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.

Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer.

Br J Cancer. 2018 Apr;118(8):1084-1088. doi: 10.1038/s41416-018-0005-1. Epub 2018 Mar 9.

PMID:
29523831
18.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.

Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer.

Br J Cancer. 2018 Apr;118(7):947-954. doi: 10.1038/s41416-018-0004-2. Epub 2018 Mar 8.

PMID:
29515256
19.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM.

Lancet Oncol. 2018 Mar;19(3):e151-e160. doi: 10.1016/S1470-2045(18)30098-6. Review.

PMID:
29508762
20.

The PLIANT trial gives trustworthy data.

Glimelius B, Kowalski J, Näsström J.

Acta Oncol. 2018 Jun;57(6):864-866. doi: 10.1080/0284186X.2018.1433876. Epub 2018 Feb 2. No abstract available.

PMID:
29392966
21.

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, Wotherspoon A, Capdevila J, Glimelius B, Tarazona N, Begum R, Lote H, Hulkki Wilson S, Mentrasti G, Brown G, Tait D, Oates J, Valeri N.

Sci Rep. 2018 Jan 23;8(1):1445. doi: 10.1038/s41598-018-19212-5.

22.

Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data meta-analysis of 22 RCTs.

Kalter J, Verdonck-de Leeuw IM, Sweegers MG, Aaronson NK, Jacobsen PB, Newton RU, Courneya KS, Aitken JF, Armes J, Arving C, Boersma LJ, Braamse AMJ, Brandberg Y, Chambers SK, Dekker J, Ell K, Ferguson RJ, Gielissen MFM, Glimelius B, Goedendorp MM, Graves KD, Heiney SP, Horne R, Hunter MS, Johansson B, Kimman ML, Knoop H, Meneses K, Northouse LL, Oldenburg HS, Prins JB, Savard J, van Beurden M, van den Berg SW, Brug J, Buffart LM.

Psychooncology. 2018 Apr;27(4):1150-1161. doi: 10.1002/pon.4648. Epub 2018 Mar 15. Review.

23.

What treatments should be skipped or intensified in localized rectal cancer?

Glimelius B.

Future Oncol. 2018 Feb;14(4):313-318. doi: 10.2217/fon-2017-0492. Epub 2018 Jan 10. No abstract available.

PMID:
29318918
24.

Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register.

Chen L, Eloranta S, Martling A, Glimelius I, Neovius M, Glimelius B, Smedby KE.

Radiother Oncol. 2018 Mar;126(3):424-430. doi: 10.1016/j.radonc.2017.12.008. Epub 2018 Jan 3.

PMID:
29306497
25.

More than 1000 new manuscripts in 2017.

Glimelius B.

Acta Oncol. 2018 Feb;57(2):174-175. doi: 10.1080/0284186X.2017.1423181. Epub 2018 Jan 5. No abstract available.

PMID:
29303398
26.

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma.

Bernatsky S, Velásquez García HA, Spinelli JJ, Gaffney P, Smedby KE, Ramsey-Goldman R, Wang SS, Adami HO, Albanes D, Angelucci E, Ansell SM, Asmann YW, Becker N, Benavente Y, Berndt SI, Bertrand KA, Birmann BM, Boeing H, Boffetta P, Bracci PM, Brennan P, Brooks-Wilson AR, Cerhan JR, Chanock SJ, Clavel J, Conde L, Cotenbader KH, Cox DG, Cozen W, Crouch S, De Roos AJ, de Sanjose S, Di Lollo S, Diver WR, Dogan A, Foretova L, Ghesquières H, Giles GG, Glimelius B, Habermann TM, Haioun C, Hartge P, Hjalgrim H, Holford TR, Holly EA, Jackson RD, Kaaks R, Kane E, Kelly RS, Klein RJ, Kraft P, Kricker A, Lan Q, Lawrence C, Liebow M, Lightfoot T, Link BK, Maynadie M, McKay J, Melbye M, Molina TJ, Monnereau A, Morton LM, Nieters A, North KE, Novak AJ, Offit K, Purdue MP, Rais M, Riby J, Roman E, Rothman N, Salles G, Severi G, Severson RK, Skibola CF, Slager SL, Smith A, Smith MT, Southey MC, Staines A, Teras LR, Thompson CA, Tilly H, Tinker LF, Tjonneland A, Turner J, Vajdic CM, Vermeulen RCH, Vijai J, Vineis P, Virtamo J, Wang Z, Weinstein S, Witzig TE, Zelenetz A, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Zucca M, Clarke AE.

Lupus Sci Med. 2017 Nov 12;4(1):e000187. doi: 10.1136/lupus-2016-000187. eCollection 2017.

27.

Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study.

Babaei M, Balavarca Y, Jansen L, Lemmens V, van Erning FN, van Eycken L, Vaes E, Sjövall A, Glimelius B, Ulrich CM, Schrotz-King P, Brenner H.

Int J Cancer. 2018 Apr 1;142(7):1480-1489. doi: 10.1002/ijc.31168. Epub 2017 Dec 4.

28.

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT).

Glimelius B, Manojlovic N, Pfeiffer P, Mosidze B, Kurteva G, Karlberg M, Mahalingam D, Buhl Jensen P, Kowalski J, Bengtson M, Nittve M, Näsström J.

Acta Oncol. 2018 Mar;57(3):393-402. doi: 10.1080/0284186X.2017.1398836. Epub 2017 Nov 15.

PMID:
29140155
29.

Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer.

Mezheyeuski A, Strell C, Hrynchyk I, Guren TK, Dragomir A, Doroshenko T, Pashkova O, Gorgun J, Ruksha K, Pfeiffer P, Kure EH, Sorbye H, Edler D, Martling A, Glimelius B, Östman A, Portyanko A.

Virchows Arch. 2018 Mar;472(3):395-405. doi: 10.1007/s00428-017-2263-3. Epub 2017 Nov 13.

30.

Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes.

Babaei M, Jansen L, Balavarca Y, Sjövall A, Bos A, van de Velde T, Moreau M, Liberale G, Gonçalves AF, Bento MJ, Ulrich CM, Schrotz-King P, Lemmens V, Glimelius B, Brenner H.

Clin Colorectal Cancer. 2018 Mar;17(1):e129-e142. doi: 10.1016/j.clcc.2017.09.002. Epub 2017 Sep 28.

31.

The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.

Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, O'Reilly DA, Izbicki JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Padbury R, Shannon J, Dervenis C, Glimelius B, Deakin M, Anthoney A, Lerch MM, Mayerle J, Oláh A, Rawcliffe CL, Campbell F, Strobel O, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer.

Ann Surg. 2017 Oct 24. doi: 10.1097/SLA.0000000000002557. [Epub ahead of print]

PMID:
29068800
32.

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.

Sclafani F, Brown G, Cunningham D, Wotherspoon A, Mendes LST, Balyasnikova S, Evans J, Peckitt C, Begum R, Tait D, Tabernero J, Glimelius B, Roselló S, Thomas J, Oates J, Chau I.

Br J Cancer. 2017 Nov 7;117(10):1478-1485. doi: 10.1038/bjc.2017.320. Epub 2017 Sep 21.

33.

Prognostic factors in patients with loco-regionally advanced gastric cancer.

Hultman B, Gunnarsson U, Nygren P, Sundbom M, Glimelius B, Mahteme H.

World J Surg Oncol. 2017 Sep 15;15(1):172. doi: 10.1186/s12957-017-1243-z.

34.

A pathology atlas of the human cancer transcriptome.

Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnström H, Glimelius B, Sjöblom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F.

Science. 2017 Aug 18;357(6352). pii: eaan2507. doi: 10.1126/science.aan2507.

PMID:
28818916
35.

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Winther SB, Österlund P, Berglund Å, Glimelius B, Qvortrup C, Sorbye H, Pfeiffer P; - on behalf of the Academy of Geriatric Cancer Research (AgeCare).

BMC Cancer. 2017 Aug 16;17(1):548. doi: 10.1186/s12885-017-3526-8.

36.

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.

Siesing C, Sorbye H, Dragomir A, Pfeiffer P, Qvortrup C, Pontén F, Jirström K, Glimelius B, Eberhard J.

PLoS One. 2017 Aug 11;12(8):e0182512. doi: 10.1371/journal.pone.0182512. eCollection 2017.

37.

What conclusions can be drawn from the Stockholm III rectal cancer trial in the era of watch and wait?

Glimelius B, Martling A.

Acta Oncol. 2017 Sep;56(9):1139-1142. doi: 10.1080/0284186X.2017.1344359. Epub 2017 Jul 7. No abstract available.

PMID:
28686505
38.

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlström H, Bill-Axelson A, Birgisson H, Björ O, Edqvist PH, Hansson T, Helleday T, Hellman P, Henriksson K, Hesselager G, Hultdin M, Häggman M, Höglund M, Jonsson H, Larsson C, Lindman H, Ljuslinder I, Mindus S, Nygren P, Pontén F, Riklund K, Rosenquist R, Sandin F, Schwenk JM, Stenling R, Stålberg K, Stålberg P, Sundström C, Thellenberg Karlsson C, Westermark B, Bergh A, Claesson-Welsh L, Palmqvist R, Sjöblom T.

Acta Oncol. 2018 Feb;57(2):187-194. doi: 10.1080/0284186X.2017.1337926. Epub 2017 Jun 20.

PMID:
28631533
39.

Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.

Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM.

Eur J Cancer. 2017 Aug;81:26-35. doi: 10.1016/j.ejca.2017.04.026. Epub 2017 Jun 6.

PMID:
28595137
40.

Need for adjuvant chemotherapy after colon cancer surgery - has it decreased?

Böckelman C, Glimelius B.

Acta Oncol. 2017 May;56(5):629-633. doi: 10.1080/0284186X.2017.1317924. No abstract available.

PMID:
28447563
41.

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM.

Br J Cancer. 2017 May 9;116(10):1271-1278. doi: 10.1038/bjc.2017.93. Epub 2017 Apr 11.

42.

Development of anxiety, depression and health-related quality of life in oncology patients without initial symptoms according to the Hospital Anxiety and Depression Scale - a comparative study.

Thalén-Lindström A, Glimelius B, Johansson B.

Acta Oncol. 2017 Aug;56(8):1094-1102. doi: 10.1080/0284186X.2017.1305124. Epub 2017 Mar 24.

PMID:
28339305
43.

On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery.

Glimelius B.

Ups J Med Sci. 2017 Mar;122(1):1-10. doi: 10.1080/03009734.2016.1274806. Epub 2017 Feb 24. Review.

44.

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.

Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, Johansson H, Machado M, Hjern F, Hallböök O, Syk I, Glimelius B, Martling A.

Lancet Oncol. 2017 Mar;18(3):336-346. doi: 10.1016/S1470-2045(17)30086-4. Epub 2017 Feb 10.

PMID:
28190762
45.

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, Holroyd A, Joseph V, Sunter NJ, Nieters A, Bea S, Monnereau A, Martin-Garcia D, Goldin LR, Clot G, Teras LR, Quintela I, Birmann BM, Jayne S, Cozen W, Majid A, Smedby KE, Lan Q, Dearden C, Brooks-Wilson AR, Hall AG, Purdue MP, Mainou-Fowler T, Vajdic CM, Jackson GH, Cocco P, Marr H, Zhang Y, Zheng T, Giles GG, Lawrence C, Call TG, Liebow M, Melbye M, Glimelius B, Mansouri L, Glenn M, Curtin K, Diver WR, Link BK, Conde L, Bracci PM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Boffetta P, Brennan P, Maynadie M, McKay J, Albanes D, Weinstein S, Wang Z, Caporaso NE, Morton LM, Severson RK, Riboli E, Vineis P, Vermeulen RC, Southey MC, Milne RL, Clavel J, Topka S, Spinelli JJ, Kraft P, Ennas MG, Summerfield G, Ferri GM, Harris RJ, Miligi L, Pettitt AR, North KE, Allsup DJ, Fraumeni JF, Bailey JR, Offit K, Pratt G, Hjalgrim H, Pepper C, Chanock SJ, Fegan C, Rosenquist R, de Sanjose S, Carracedo A, Dyer MJ, Catovsky D, Campo E, Cerhan JR, Allan JM, Rothman N, Houlston R, Slager S.

Nat Commun. 2017 Feb 6;8:14175. doi: 10.1038/ncomms14175.

46.

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer.

Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.

47.

Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer.

Mathot L, Kundu S, Ljungström V, Svedlund J, Moens L, Adlerteg T, Falk-Sörqvist E, Rendo V, Bellomo C, Mayrhofer M, Cortina C, Sundström M, Micke P, Botling J, Isaksson A, Moustakas A, Batlle E, Birgisson H, Glimelius B, Nilsson M, Sjöblom T.

Cancer Res. 2017 Apr 1;77(7):1730-1740. doi: 10.1158/0008-5472.CAN-16-1921. Epub 2017 Jan 20.

48.

Reply to C.F. Hess et al.

Carde PP, Grynberg M, Poirot C, Glimelius B, Mounier N.

J Clin Oncol. 2017 Jan 20;35(3):374. doi: 10.1200/JCO.2016.69.7995. Epub 2016 Oct 28. No abstract available.

PMID:
28095265
49.

Two countries - Two treatment strategies for rectal cancer.

Glimelius B, Myklebust TÅ, Lundqvist K, Wibe A, Guren MG.

Radiother Oncol. 2016 Dec;121(3):357-363. doi: 10.1016/j.radonc.2016.11.010. Epub 2016 Nov 23.

PMID:
27887734
50.

Supplemental Content

Loading ...
Support Center